We are live on ! Find out more
CC

Casdin Capital Portfolio holdings

AUM $1.32B
1-Year Est. Return 76.62%
This Fund
S&P 500
This Quarter Est. Return
-1.1%
1 Year Est. Return
+76.62%
3 Year Est. Return
+218.92%
5 Year Est. Return
+86.82%
10 Year Est. Return
+4,823.46%
AUM
$3.36B
AUM Growth
-$17.8M
Cap. Flow
+$178M
Cap. Flow %
5.3%
Top 10 Hldgs %
63.12%
Holding
56
New
4
Increased
15
Reduced
6
Closed
8

Top Buys

Rank Stock Value
1
EXAS
Exact Sciences
EXAS
+$120M
2
BEAM icon
Beam Therapeutics
BEAM
+$34.1M
3
FATE icon
Fate Therapeutics
FATE
+$33.5M
4
ADPT icon
Adaptive Biotechnologies
ADPT
+$23.6M
5
ORTX
Orchard Therapeutics plc American Depositary Shares
ORTX
+$22.8M

Top Sells

Rank Stock Value
1
BLUE
bluebird bio
BLUE
+$39.6M
2
BNR
Burning Rock Biotech
BNR
+$32.7M
3
IOVA icon
Iovance Biotherapeutics
IOVA
+$25.5M
4
RLAY icon
Relay Therapeutics
RLAY
+$18.8M
5
ADVM
Adverum Biotechnologies
ADVM
+$17.3M

Sector Composition

Rank Sector Weight
1 Healthcare 86.11%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALEC icon
26
Alector
ALEC
$168M
$33.2M 0.99%
1,650,000
– –
CRSP icon
27
CRISPR Therapeutics
CRSP
$4.88B
$32.5M 0.97%
266,430
– –
ZLAB icon
28
Zai Lab
ZLAB
$2.05B
$25.4M 0.76%
190,000
– –
ORTX
29
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
$23.3M 0.7%
+321,543
New +$22.8M
BNR
30
Burning Rock Biotech
BNR
$93.2M
$22.8M 0.68%
84,715
-107,500
-56% -$32.7M
SNDX icon
31
Syndax Pharmaceuticals
SNDX
$1.7B
$22.4M 0.67%
1,000,000
+550,000
+122% +$12.4M
ADVM
32
DELISTED
Adverum Biotechnologies
ADVM
$21.8M 0.65%
221,162
-143,838
-39% -$17.3M
MASS icon
33
908 Devices
MASS
$345M
$19.7M 0.59%
406,502
– –
KRON
34
DELISTED
Kronos Bio
KRON
$17.1M 0.51%
583,436
– –
TSHA icon
35
Taysha Gene Therapies
TSHA
$1.66B
$16.7M 0.5%
820,440
– –
ORIC icon
36
Oric Pharmaceuticals
ORIC
$1.1B
$14.7M 0.44%
601,515
– –
FULC icon
37
Fulcrum Therapeutics
FULC
$283M
$14.6M 0.44%
1,241,176
– –
DBTX
38
DELISTED
Decibel Therapeutics, Inc. Common Stock
DBTX
$13M 0.39%
+1,146,421
New +$18M
CELL
39
DELISTED
PhenomeX Inc. Common Stock
CELL
$10M 0.3%
200,000
– –
DYN icon
40
Dyne Therapeutics
DYN
$4.71B
$9.47M 0.28%
610,000
+240,000
+65% +$4.64M
SEER icon
41
Seer Inc
SEER
$123M
$7.5M 0.22%
150,000
– –
TPTX
42
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
$7.09M 0.21%
75,000
– –
SGMO
43
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$6.89M 0.21%
550,000
-530,000
-49% -$7.14M
CLOV icon
44
Clover Health Investments
CLOV
$2.28B
$5.49M 0.16%
+726,511
New +$8.2M
STOK icon
45
Stoke Therapeutics
STOK
$1.84B
$4.66M 0.14%
120,000
– –
FHTX icon
46
Foghorn Therapeutics
FHTX
$271M
$2.85M 0.08%
216,216
– –
SANA icon
47
Sana Biotechnology
SANA
$885M
$2.01M 0.06%
+60,000
New +$1.95M
CDAK
48
DELISTED
Codiak BioSciences, Inc. Common Stock
CDAK
$1.16M 0.03%
76,688
– –
ABCL icon
49
AbCellera Biologics
ABCL
$1.78B
– –
-200,000
Closed -$8.05M
BDTX icon
50
Black Diamond Therapeutics
BDTX
$99.7M
– –
-289,395
Closed -$9.28M
1
2
3

Similar funds

MDSL
M.D. Sass LLC New York $1.32B AUM 16.01% 1-Year Est. Return
CP
Cumberland Partners Toronto, Ontario, Canada $1.32B AUM 27.83% 1-Year Est. Return
HCM
Hilton Capital Management Garden City, New York $1.32B AUM 15.59% 1-Year Est. Return
MRL
Mantle Ridge LP New York $1.33B AUM 11.36% 1-Year Est. Return
SWM
SHP Wealth Management Plymouth, Massachusetts $1.33B AUM
B
BloombergSen Toronto, Ontario, Canada $1.31B AUM 8.32% 1-Year Est. Return
WGAM
Wilkinson Global Asset Management New York $1.31B AUM 17.03% 1-Year Est. Return
CRAM
Compass Rose Asset Management New York $1.33B AUM 2.38% 1-Year Est. Return

Casdin Capital's Q1 2021 Portfolio in Review

As of Q1 2021, Casdin Capital held 56 positions worth $3.36B, down 0.53% from $3.38B the previous quarter. Its ten largest holdings account for 63% of the portfolio.

Casdin Capital deployed $178M of net new capital in Q1 2021, opening 4 new positions and adding to 15 existing holdings. Its largest new stake was Orchard Therapeutics plc American Depositary Shares: 321,543 shares worth $23.3M.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, up from 84% a quarter earlier.

On the sell side, the largest reduction was Burning Rock Biotech, an estimated $32.7M trimmed.

  • Casdin Capital's largest Q1 2021 buy was Orchard Therapeutics plc American Depositary Shares: 321,543 shares worth $23.3M.
  • Casdin Capital added most to Exact Sciences in Q1 2021, an estimated $120M increase.
  • Casdin Capital's biggest Q1 2021 reduction was Burning Rock Biotech, cutting an estimated $32.7M.
  • Casdin Capital fully exited bluebird bio in Q1 2021, selling an estimated $39.6M.
  • Casdin Capital's ten largest holdings make up 63% of its $3.36B portfolio in Q1 2021.
  • Casdin Capital opened 4 new positions and closed 8 in Q1 2021.
  • Casdin Capital's portfolio value fell 0.53% quarter-over-quarter to $3.36B.

Based on Casdin Capital's 13F filing for Q1 2021, filed 17 May 2021.